Sign inJoin waitlistJoin the waitlist

Judy Felgenhauer

Physician · Providence

Credentials: · · ·

History

Providence
Present

University of Washington Department Hematology Oncology
1993–1996
Fred Hutchinson Cancer Research Center
Children's Hospital and Medical Center
1990–1993
University of Washington School of Medicine
1986–1990

Research

Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia
Clinical Cancer Research · 2004 · 79 citations
A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of…
Pediatric Blood & Cancer · 2013 · First of 12 authors · Corresponding · 50 citations
Children's Oncology Group's 2013 blueprint for research: adolescent and young adult oncology
Review · Pediatric Blood & Cancer · 2013 · 48 citations

Douglas Hawkins
7 papers
JD
James Douglas
3 papers
Julie Park
3 papers
Neyssa Marina
3 papers
JM
James Miser
2 papers
JH
Joanne Hilden
2 papers
Judith Margolin
2 papers
Kathleen Sakamoto
2 papers
RW
Richard Womer
2 papers
SV
Sarah Vaiselbuh
2 papers · 1 as a fellow
Sarangarajan Ranganathan
2 papers
SL
Skyler Lindsley
2 papers

Clinical trials

Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
Study chair · Completed · Phase 2
Children's Oncology Group
2004–2013
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2033
Quality of End-of-Life Care for Children With Cancer
Site PI · Recruiting
Children's Oncology Group
2026–2031
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028